Rocket Lab has given investors whiplash. On one hand, the company just completed a qualification test of the Archimedes engine for its new Neutron rocket, nailed a rapid-response military launch for the US Space Force in under 17 hours, and counts Morgan Stanley among its bulls with a $105 price target. On the other, the stock cratered more than 11% in a single session after Piper Sandler initiated coverage with a “Neutral” rating and an $83 target — a move that also dragged down sector peers such as AST SpaceMobile.
The sell-off, which sent the stock to a close of $67.35 on elevated volume of over 31 million shares, was triggered not by a downgrade or a miss, but by the simple act of a new analyst picking up coverage. Piper Sandler’s Alexander Potter assigned Rocket Lab a “Neutral” while handing AST SpaceMobile an “Overweight” and SpaceX a “Neutral” with a $156 target. Potter acknowledged Rocket Lab as “the strongest publicly traded SpaceX alternative,” pointing to its nearly 90 successful Electron launches and vertically integrated model. His hesitation: even after the recent pullback, he sees the stock as fully valued over a 12-month horizon.
Adding to the market jitters, CEO Peter Beck’s trust sold 3.28 million shares of Rocket Lab stock across 24 transactions between July 6 and July 8. That sale was hardly a knee-jerk reaction: the trust had put a Rule 10b5-1 trading plan in place on March 27, 2026, months before any analyst coverage began, with diversification, estate planning and philanthropy cited as reasons. After the sales, the trust still holds roughly 90% of Beck’s combined direct and indirect stake — 2.45 million shares indirectly and 491,930 directly. One market participant called the narrative “overblown,” noting the plan was disclosed long ago.
At the core of investor caution is Rocket Lab’s planned $8 billion acquisition of Iridium Communications, which requires a $3.6 billion bridge financing. Piper Sandler sees significant dilution risk for existing shareholders, a concern echoed by Seeking Alpha, which argued the deal doesn’t make the stock genuinely cheaper despite optically low valuation multiples. The broader space sector hasn’t helped: AST SpaceMobile and SpaceX also suffered double-digit percentage losses in the same period, spurred by their own capital moves and a failed Starship test flight.
Should investors sell immediately? Or is it worth buying Rocket Lab?
Yet the operational picture tells a different story. Rocket Lab completed its qualification test of the Archimedes engine — producing 1.5 million pounds of thrust for Neutron’s first stage — and conducted a full hot-fire test of the AVac vacuum engine for the upper stage, which delivers roughly 1.2 times the thrust of the first-stage engine. The two-stage rocket sports an unusual nose cone nicknamed “Hungry Hippo.” The maiden flight of Neutron, originally targeted for late 2025, was pushed to the first half of 2026 after a tank rupture in January, though some analysts now pencil in the fourth quarter of 2026. In a separate operational win, Rocket Lab’s Electron launched a satellite for the US Space Force’s Victus Haze exercise just 16 hours and 42 minutes after receiving the order — well inside the 24-hour deadline — on a mission worth roughly $32 million.
Wall Street remains deeply divided. Morgan Stanley reiterated its “Overweight” rating with a $105 target, even raising its bull-case scenario from $185 to $293, citing greater launch and connectivity potential from the Iridium tie-up. Cantor Fitzgerald reaffirmed “Overweight” on June 30 with a $96 price target. Meanwhile, the stock’s 14-day relative strength index has fallen to around 30, flirting with oversold territory. Some institutional investors are stepping in: Wealthfront Advisers increased its stake by 62.8%, to 191,529 shares worth roughly $12.3 million. But other insiders sold at much higher levels — Frank Klein offloaded 44,390 shares at $142.57, and Arjun Kampani sold 88,000 at $107.98.
Rocket Lab is effectively trading on two tracks: a short-term narrative of valuation caution, insider sales and Iridium-related dilution, versus a longer-term story of reusable rocket technology, steady launch cadence and a burgeoning vertical integration model. The outcome likely depends on two key catalysts: clarity on the Iridium financing structure and continued progress toward the first Neutron flight — a timeline that remains in motion.
Ad
Rocket Lab Stock: Buy or Sell?! New Rocket Lab Analysis from July 18 delivers the answer:
The latest Rocket Lab figures speak for themselves: Urgent action needed for Rocket Lab investors. Is it worth buying or should you sell? Find out what to do now in the current free analysis from July 18.
Rocket Lab: Buy or sell? Read more here...
